ProKidney (PROK) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
REGENXBIO (RGNX) has outperformed ProKidney (PROK) over the past year, losing 39.3% versus a loss of 52.5%. Over five years, RGNX leads with a -76.9% price change compared with -89.5% for PROK. REGENXBIO is the larger company by market cap ($473.4 million vs $415.2 million), about 1.1 times the size, while ProKidney is growing revenue faster (+1075.0% vs +104.5%).
REGENXBIO converts more of its revenue into profit, with a net margin of -113.8% versus -7725.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | RGNX |
|---|---|---|
| Share price | $1.04 | $7.16 |
| Market cap | $415.21M | $473.44M |
| 1-day change | -1.89% | -0.28% |
| YTD return | -53.57% | -50.28% |
| 1-year return | -52.51% | -39.32% |
| 5-year return | -89.49% | -76.87% |
| EPS (TTM) | $-0.61 | $-3.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $893.00K | $170.44M |
| Revenue growth (YoY) | +1075.00% | +104.54% |
| Net income (latest FY) | $-68.99M | $-193.88M |
| Operating margin | -18477.83% | -94.58% |
| Net margin | -7725.20% | -113.75% |
| 52-week high | $2.65 | $16.19 |
| 52-week low | $0.87 | $5.46 |
| Distance from 52-week high | -60.75% | -55.78% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +525.00% | +198.88% |
| Average volume | 1.44M | 1.39M |
| Shares outstanding | 209.63M | 66.12M |
| Employees | 231 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RGNX has outperformed PROK by 13.2 percentage points over the past year.
- REGENXBIO is more profitable, keeping -113.8 cents of every revenue dollar as net income versus -7725.2 cents for ProKidney.
- ProKidney grew revenue faster in its latest fiscal year (+1075.00% vs +104.54%).
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
PROK vs RGNX FAQ
Which is bigger, ProKidney or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $415.21M for ProKidney (PROK).
Which stock has performed better over the past year, PROK or RGNX?
RGNX returned -39.32% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.